ProKidney Corp.

NasdaqCM PROK

ProKidney Corp. Revenue for the Trailing 12 Months (TTM) ending September 30, 2024: USD 4.49 M

ProKidney Corp. Revenue is USD 4.49 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

ProKidney Corp. Revenue for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
ProKidney Corp. Revenue for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
ProKidney Corp. Revenue for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

NasdaqCM: PROK

ProKidney Corp.

CEO	Dr. Bruce Culleton M.D.
IPO Date	June 30, 2021
Location	United States
Headquarters	2000 Frontis Plaza Blvd.
Employees	163
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Key trends

Past 5 years